Paraneoplastic antibody during follow-up of a patient with anti-Ri-associated paraneoplastic neurological syndrome

Acta Neurologica Scandinavica

Volumn 119, Issue 5, 2009, Pages 338-340

  Stich, O ^a   Rasiah, C ^b   Rauer, Sebastian ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RAVO DIAGNOSTIKA GMBH   (Germany)

Author keywords

ANNA 2; Anti Ri; FDG PET; Follow up; Paraneoplastic neurological syndromes; Semiquantitative ELISA

Indexed keywords

ANTIBODY; FLUORODEOXYGLUCOSE F 18; PARANEOPLASTIC ANTIBODY; RI ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CANCER RELAPSE; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY;

ANTIBODIES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA; CEREBELLAR DISEASES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATAL OUTCOME; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MEDIASTINUM; NEOPLASM RECURRENCE, LOCAL; NERVE TISSUE PROTEINS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 64549090279     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01102.x     Document Type: Article

References (5)

1. Stich O, Rauer S. Qualitative evidence of anti-Ri specific intrathecal antibody synthesis and quantification of anti-Ri antibodies in serial samples from a patient with anti-Ri syndrome. J Neurol Neurosurg Psychiatry 2006 77 : 282 3.
2. Graus F, Delattre JY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004 75 : 1135 40.
3. Rauer S, Czygan M, Kaiser R. Quantification of circulating anti-Hu antibody in serial samples from patients with paraneoplastic neurological syndromes: possible correlation of antibody concentration and course of neurological symptoms. J Neurol 2002 249 : 285 9.
4. Lladó A, Mannucci P, Carpentier AF et al. Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 2004 63 : 1947 9.
5. Vedeler CA, Antoine JC, Giometto B et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006 13 : 682 90.